CureVac Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

CureVac şirketinin toplam hissedar öz sermayesi €376.5M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €556.8M ve €180.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€202.52m
Eşitlik	€376.53m
Toplam yükümlülükler	€180.30m
Toplam varlıklar	€556.84m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 5CV 'nin kısa vadeli varlıkları ( €251.6M ) kısa vadeli yükümlülüklerini ( €110.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 5CV şirketinin kısa vadeli varlıkları ( €251.6M ) uzun vadeli yükümlülüklerini ( €70.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 5CV borçsuzdur.

Borcun Azaltılması: 5CV şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 5CV şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 5CV tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

CureVac Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Forecast to breakeven in 2024

CureVac N.V. to Report Q3, 2024 Results on Nov 12, 2024

Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024

CureVac N.V. to Present at the Society for Immunotherapy of Cancer 39th Annual Meeting

CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Second quarter 2024 earnings released: €0.32 loss per share (vs €0.30 loss in 2Q 2023)

CureVac N.V. Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac N.V. to Report Q2, 2024 Results on Aug 15, 2024

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings released: €1.18 loss per share (vs €1.32 loss in FY 2022)

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings released: €0.25 loss per share (vs €0.25 loss in 3Q 2022)

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: €0.30 loss per share (vs €0.31 loss in 2Q 2022)

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

First quarter 2023 earnings released: €0.27 loss per share (vs €0.081 loss in 1Q 2022)

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Full year 2022 earnings released: €1.32 loss per share (vs €2.21 loss in FY 2021)

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

CureVac N.V. Announces CEO Changes

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

Second quarter 2022 earnings released: €0.31 loss per share (vs €0.82 loss in 2Q 2021)

No longer forecast to breakeven

CureVac Announces Executive Changes

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings released: €2.21 loss per share (vs €0.98 loss in FY 2020)

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Forecast breakeven moved forward to 2021

CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV

CureVac N.V. Announces Results of the Second Interim Analysis of its International Pivotal Phase 2b/3 Study in Approximatively 40,000 Subjects

CureVac N.V.’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

CureVac N.V. Develops a New Class of Transformative Medicines Based on Messenger Ribonucleic Acid

Full year 2020 earnings released: €0.98 loss per share (vs €137 loss in FY 2019)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin